Опубликована: Май 1, 2025
Язык: Английский
Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 79, С. 29 - 38
Опубликована: Авг. 24, 2024
Язык: Английский
Процитировано
14
Journal of Medical Virology, Год журнала: 2025, Номер 97(2)
Опубликована: Янв. 27, 2025
ABSTRACT While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) effectively manage chronic hepatitis B, their long‐term effects on lipid metabolism cardiovascular outcomes remain unclear. This study compares the impact of ETV, TDF, treatment‐naïve (control group) hyperlipidemia major adverse cardiac events (MACE) in people living with B (PLWHB). We used claim data from South Korean National Health Insurance Service. Propensity score matching was to account for confounding factors. The 5‐year cumulative incidence dyslipidemia 7.10% 12.17% 18.55% control group, rates per 1000 person‐years 14.5, 25.5, 38.9, respectively. TDF showed a significantly lower risk compared ETV (IRR: 0.56, p < 0.001) which confirmed Cox regression analysis (HR: 0.392 vs. control, 0.001). For MACE, 9.11% 10.98% 12.32% 18.4, 22.5, 24.8, demonstrated reduced 0.817, 0.001), similarly supported by 0.728 In conclusion, not only reduces but is also associated MACE or treatment‐naive group PLWHB.
Язык: Английский
Процитировано
2
Liver International, Год журнала: 2025, Номер 45(5)
Опубликована: Апрель 21, 2025
ABSTRACT Background The prevalence of diabetes is increasing among chronic hepatitis B (CHB) patients. However, the relative efficacy sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 (DPP4i), compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), such at‐risk populations remains unclear in terms reducing liver‐related events (LRE). Methods Using a nationwide database (2019–2022), we identified CHB patients (age ≥ 40) and established two new‐user cohorts: SGLT2i vs. GLP‐1RA DPP4i GLP‐1RA. LREs included hepatocellular carcinoma, cirrhosis, liver transplantation mortality. For appropriate balancing, propensity score matching (PSM) was performed for each cohort. Multivariate Cox regression models were used to estimate LRE risk adjusted hazard ratios (aHR) 95% confidence intervals (CI). Results Propensity provided separate (1) ( n = 2297) 461) (2) 803) 165) users. similar across comparison, aHRs 0.82 (95% CI 0.49–1.37) (vs. SGLT2i) 0.93 0.41–2.07) DPP4i), indicating no significant differences. Subgroup analyses showed trend favouring over females, obese individuals, antiviral therapy (AVT) users, those complications, longer duration physically active individuals. Compared DPP4i, observed AVT users shorter duration, though none statistically significant. Conclusion Overall comparable between Further prospective studies are required identify who can benefit from specific medication.
Язык: Английский
Процитировано
2
Journal of Ethnopharmacology, Год журнала: 2025, Номер unknown, С. 119560 - 119560
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
1
Journal of Gastroenterology and Hepatology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 27, 2025
ABSTRACT Introduction Studies have shown a change in the etiological profile of liver cancer globally. We aimed to analyze burden and changes etiology Asia‐Oceania region. Methods The was estimated using data from 2021 Global Burden Disease (GBD) Study. analysis included age‐standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), disability‐adjusted life years (DALY) per 100 000 population. Results region contributed 68.6%, 68.8%, 67.3% global incidence, prevalence, 2021. In 2021, Mongolia, Tonga, South Korea had highest ASIR, ASPR, ASMR, whereas Australia, New Zealand, Guam greatest increase rates. Viral hepatitis remained most common cancer, with 47.7% 26.1% cases being related B virus (HBV) C (HCV), respectively. Around 14.5% 7.1% were alcohol nonalcoholic steatohepatitis (NASH), respectively; however, annual ASIR for NASH. Alcohol, drug abuse, tobacco use, metabolic syndrome, 15.2%, 11.7%, 11.5%, 9.0% 2021; death 1990 syndrome. Conclusion remains cause NASH having rate deaths Asia‐Oceania.
Язык: Английский
Процитировано
1
Medical Oncology, Год журнала: 2025, Номер 42(4)
Опубликована: Март 17, 2025
Язык: Английский
Процитировано
1
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7191 - 7191
Опубликована: Июнь 29, 2024
Hepatocellular carcinoma (HCC) is the most frequent among primary liver tumors (90%) and one of main causes cancer-related death. It develops usually in a chronically inflamed environment, ranging from compensatory parenchymal regeneration to fibrosis cirrhosis: carcinogenesis can potentially happen each these stages. Inflammation determined by chronic viral infection (hepatitis B, hepatitis C, delta viruses) represents an important risk factor for HCC etiology through both direct damage immune-related mechanisms. The deregulation physiological immunological network lead carcinogenesis. recent introduction immunotherapy as gold-standard first-line treatment highlights role immune system inflammation double-edged weapon treatment. In this review we highlight how key hepatocarcinogenesis viral, alcohol metabolic diseases.
Язык: Английский
Процитировано
6
JHEP Reports, Год журнала: 2024, Номер 7(4), С. 101313 - 101313
Опубликована: Дек. 24, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition. We investigated whether statin use reduces liver-related events (LREs) risk among patients with MASLD or increased alcohol intake (MetALD). This nationwide cohort study included individuals aged ≥40 years MASLD/MetALD undergoing health examinations between 2012 and 2013. The primary outcome was LREs; hepatocellular carcinoma (HCC), decompensated cirrhosis (DLC), mortality. Secondary outcomes HCC, DLC, (SLD) regression, all-cause mortality, cardiovascular diseases (CVD)-related respectively. Multivariable Cox regression performed to estimate the of LREs associated use. Among 516,575 (median follow-up: 10.1 years), users experienced significantly lower LRE rates (1.6%) compared non-users (2.0%, p <0.001). analysis revealed that reduced risks (adjusted hazard ratio [aHR] 0.64, 95% CI 0.61-0.68), HCC (aHR 0.52, 0.47-0.58), DLC 0.58, 0.52-0.65), mortality 0.81, 0.78-0.84), CVD-related 0.87, 0.80-0.95), 0.51, 0.46-0.57). Furthermore, SLD 1.18, 1.15-1.21). Stratified analyses consistently demonstrated reductions across all subgroups, particularly in elevated alanine aminotransferase levels. Sensitivity confirmed robustness these associations. Statins are MASLD, especially those levels, suggesting viable preventive strategy for such population. Our provides critical evidence supporting role statins reducing metabolic (MASLD), condition significant global impact. These findings relevant clinicians managing high-risk as they highlight potential mitigate both risks. By demonstrating results through comprehensive sensitivity stratified analyses, our research underscores importance integrating therapy into management MASLD. has practical implications physicians, researchers, policymakers developing guidelines strategies improve long-term outcomes.
Язык: Английский
Процитировано
4
The Korean Journal of Internal Medicine, Год журнала: 2024, Номер 39(6), С. 931 - 944
Опубликована: Окт. 24, 2024
Background/Aims: Non-alcoholic fatty liver disease (NAFLD), now the most common chronic worldwide, has become a significant public health concern. This study aims to analyze evolving epidemiology of NAFLD in South Korea.Methods: We utilized claim data from Korean National Health Insurance Service 2010 2022 NAFLD’s incidence, prevalence, and progression.Results: From 2022, incidence prevalence rates each increased 1.87% 4.47% 10.49% 17.13%, respectively. The differences between urban rural areas were minimal 2012 yet both showed increases over decade. group had higher comorbidities compared control group, comorbid condition was hypertension. Moreover, ten-year malignancy, heart disease, stroke 13.42%, 15.72%, 8.36%, respectively, which significantly than those group. cirrhosis hepatocellular carcinoma 10 years 2.22% 0.77%, total medical costs patients more doubled ten all group.Conclusions: A increase its impact on healthcare utilization observed Korea. With leading serious diseases costs, integrated care strategies that include treatment lifestyle modifications are essential.
Язык: Английский
Процитировано
3
Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 7, 2025
Abstract Hepatocellular cancer (HCC) therapy is in need for an ideal companion diagnostic. Preclinical experimental studies have identified the insulin receptor (IR) and its synergistic counterpart, IGF1 (IGF1R), as relevant HCC development, ligands IGF2 been found to be elevated HCC. This study aimed bridge gap clinical setting explore whether IR or IGF1R would of prognostic significance associated with clinicopathologic parameters patients. In our retrospective cohort located at University Hospital Schleswig-Holstein, Campus Kiel, Germany, samples 139 patients were examined expression by immunohistochemistry. A HistoScore was correlated clinicopathological characteristics survival. overexpression frequently observed Membranous worse tumor specific survival ( p = 0.043). Intriguingly, membranous 0.017) subgroup undergoing sorafenib therapy. not conclusion, results suggest that plays a role prognosis treatment resistance, inspiring future validation potential diagnostic
Язык: Английский
Процитировано
0